Sonim 做了 25 年三防手机。2026-01-23 把手机业务整体卖给 NEXA 旗下的 Pace Car Acquisition，价款 $1,500 万减营运资金调整；同一天改名 DNA X, Inc.，新业务是 2025-12 用 223,201 股换来的加密交易网站 DNA X LLC。股票代码仍是 SONM。
展开推导：数字怎么来的
“The board of directors of the Company approved the Name Change pursuant to Section 242 of the General Corporation Law of the State of Delaware ("DGCL").”“The purchase price of $15,000 less a working capital adjustment of $1,550 was paid in cash and for the settlement of certain liabilities of the Company, except for $1,500 that was held back by the Buyer and is due to be paid to the Seller on October 28, 2026, less any agreed upon claims.”
“Eastern Time on October 27, 2025 (the "Effective Time"), every 18 shares of Common Stock issued and outstanding prior to the Effective Time shall, automatically and without further action by the Corporation or the holders thereof, be combined and converted into one (1) share of Common Stock (the "Reverse Split"); provided, however, no fractional shares of Common Stock shall be issued in connection with the Reverse Split, and instead, the Corporation shall pay to the stockholder of such fractional share a sum in cas …”
“(the "Company") received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Staff determined that, from July 18 to August 1, 2024, the closing bid price of the Company's common stock, par value $0.001 per share, was at $1.00 per share or greater.”“(the "Company") received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Staff determined that, from October 27, 2025 to November 11, 2025, the closing bid price of the Company's common stock, par value $0.001 per share, was at $1.00 per share or greater.”
“Based on the foregoing transactions, as of the date of the filing of this Current Report on Form 8-K/A, the Company believes it has stockholders' equity in excess of the $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market pursuant to Listing Rule 5550(b)(1) (the "Equity Rule"), as reflected in the pro forma stockholders' equity balance provided below.”
DNA Holdings 2025-12 的 $120 万票据：转股价 $5.50，带全棘轮，底价 $1.10（要股东批准才能下调），违约时按收盘价 80%。2026-05 换成 $305 万新票据：转股价 $6.00（需股东批准），违约时 80%，以 DNA X LLC 股权作担保。7/8 整张换成优先股，票据消失。
展开推导：数字怎么来的
“However, the conversion price cannot be reduced below $1.10, and no adjustment to the conversion price may be made under the "full-ratchet" adjustment or the anti-dilution adjustment, unless and until the Company has received approval from the Company's stockholders in accordance with the Nasdaq Listing Rules.”“the conversion price will be equal to 80% of the closing price of the common stock on the principal trading market on the date of conversion and (ii) upon the occurrence of a Change of Control Transaction (as defined in the Note), and subject to the prior obtainment of the Stockholder Approval, the conversion price will be equal to the lower of the closing price of the common stock on (x) the original issue date of the Note or (y) the date that the Change of Control Transaction is consummated.”
“Each share of Preferred Stock shall automatically, without further action by any Holder, convert into Common Stock on the first (1st) Trading Day (the "Conversion Date") immediately following receipt of Shareholder Approval to issue the Underlying Shares.”“The Series B Preferred Stock has no voting rights; provided, however, that the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend the Certificate of Designation, (b) create any equity securities that are senior in preference or liquidation to the Series B Preferred Stock, (c) amend its certificate of incorporatio …”
“The Company shall hold an annual or special meeting of stockholders on or prior to the date that is seventy-five (75) days following the Closing Date for the purpose of obtaining Shareholder Approval, with the recommendation of the Company's Board of Directors that such proposals are approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxi …”
“(a) The Reporting Persons each beneficially own an aggregate of 223,201 shares of common stock, which represent approximately 19.99% of the outstanding shares of common stock, based on 1,116,286 shares of common stock outstanding as of December 15, 2025.”
“On August 7, 2025, the Company and the Investors entered into an amendment, amending each of the Original Subscription Agreements (the "Subscription Agreement Amendments") to reduce the Subscription Warrant exercise price to $0.75.”
“exchange the Partitioned Note for the delivery of 148,500 shares of common stock (the "Exchange Shares"), at an effective price per Exchange Share equal to $4.24, which is below the "Minimum Price" as defined in Nasdaq Listing Rule 5635(d) (the "Exchange").”
“Up to 350,000,000 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC ("Chardan" or the "Selling Securityholder") of up to 350,000,000 shares of our common stock, par value $0.001 per share ("Common Stock"), that have been or may be issued by us to Chardan pursuant to a ChEF Purchase Agreement, dated as of September 29, 2025 (the "Signing Date"), by and between us and Chardan (the "Purchase Agreement") establishing a committed equity facili …”“In November 2025, the Company sold 12,300 shares of stock through the ChEF and received $79 in net proceeds.”
“(g) Purchaser also understands that the Purchased Interest is a "restricted security" within the meaning of Rule 144 under the Act and that unregistered re-sales may only be made in conformity with that Rule or pursuant to another available exemption from registration under the Act.”
“Pursuant to the Registration Rights Agreement, the Company has agreed to file, within 30 calendar days after the obtainment of the Stockholder Approval, a resale registration statement on Form S-3 (or Form S-1 if Form S-3 is not available) providing for the resale by DNA Holdings of the shares of Common Stock issuable upon conversion of the Series B Preferred Stock (the "Registrable Shares"), and to use commercially reasonable efforts to cause such resale registration statement to be declared effective as soon as p …”
“At the Special Meeting, a total of 886,409 shares of common stock, representing approximately 59.6% of the shares of common stock outstanding and entitled to vote, were represented at the meeting in person or by proxy, constituting a quorum.”
“(a) The Reporting Persons each beneficially own an aggregate of 223,201 shares of common stock, which represent approximately 19.99% of the outstanding shares of common stock, based on 1,116,286 shares of common stock outstanding as of December 15, 2025.”“DNA Holdings Venture Inc. filed a late Form 3 on February 20, 2026 that was required to be filed by December 27, 2025.”